ClostraBio has completed numerous supportive nonclinical studies to validate our CLB-004 program. The company has transferred our manufacturing process to a CDMO where we've successfully manufactured multiple kg-scale batches of material for nonclinical studies.
With IND-enabling toxicology studies underway, we expect to initiate a clinical study in ~12 months. Given the expected favorable safety profile of our compounds,...
ClostraBio has completed numerous supportive nonclinical studies to validate our CLB-004 program. The company has transferred our manufacturing process to a CDMO where we've successfully manufactured multiple kg-scale batches of material for nonclinical studies.
With IND-enabling toxicology studies underway, we expect to initiate a clinical study in ~12 months. Given the expected favorable safety profile of our compounds, we intend to enroll patients with mild-moderate ulcerative colitis UC in a Phase 1a/b SAD-MAD clinical study to obtain safety/tolerability data, determine our Phase 2 dose, and generate exploratory efficacy endpoints.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.